"N Engl J Med"[journal] 检索结果

1121. Catheter Ablation for Ventricular Tachycardia.

作者: Jae Hyun Byun.
来源: N Engl J Med. 2025年392卷24期2490页

1122. Catheter Ablation for Ventricular Tachycardia.

作者: Jonathan E Rosenfeld.
来源: N Engl J Med. 2025年392卷24期2489-2490页

1123. Catheter Ablation for Ventricular Tachycardia.

作者: Viktor Čulić.
来源: N Engl J Med. 2025年392卷24期2489页

1124. Autologous Transplantation of the Entire Bulbar Ocular Surface.

作者: Enrica Sarnicola.;Caterina Sarnicola.;Federica Machetta.;Michele Reibaldi.;Vincenzo Sarnicola.
来源: N Engl J Med. 2025年392卷24期2487-2489页

1125. Gene Therapy for Infantile-Onset Pompe's Disease.

作者: Giancarlo Parenti.;Nicola Brunetti-Pierri.
来源: N Engl J Med. 2025年392卷24期2477-2478页

1126. Redefining End Points in MASH Cirrhosis.

作者: Guadalupe Garcia-Tsao.
来源: N Engl J Med. 2025年392卷24期2475-2477页

1127. Cerebral Embolic Protection during TAVI - The Failed Promise.

作者: Hani Jneid.
来源: N Engl J Med. 2025年392卷24期2473-2475页

1128. Moving Past "Business as Usual" for Medical Education.

作者: Judith L Bowen.;Raja-Elie E Abdulnour.
来源: N Engl J Med. 2025年392卷24期2472-2473页

1129. Case 18-2025: A 63-Year-Old Woman with Dyspnea on Exertion.

作者: Malissa J Wood.;Carola A Maraboto Gonzalez.;Reece J Goiffon.;Eric D Jacobsen.;Bailey M Hutchison.
来源: N Engl J Med. 2025年392卷24期2459-2470页

1130. Boerhaave Syndrome.

作者: Penghui Wei.;Wenyong Zhu.
来源: N Engl J Med. 2025年392卷24期2458页

1131. Navigating the Discontinuity Crisis in Medical Education.

作者: Eric J Warm.;Sima S Desai.;Judith L Bowen.
来源: N Engl J Med. 2025年392卷24期2447-2457页

1132. AAV9-Mediated Gene Therapy for Infantile-Onset Pompe's Disease.

作者: Xiuwei Ma.;Lu Zhuang.;Wenhao Ma.;Jun Li.;Yingying Mao.;Jianhua Wang.;Xiaodong Wang.;Juan Xu.;Shuangqing Yu.;Ruijie Gu.;Yongxia Wang.;Zhongqiu Li.;Xinyang Jiang.;Sheng Zhang.;Fang He.;Xiao Yang.;Lina Zhu.;Shan Zhang.;Yanping Zhang.;Ting Li.;Qiuping Li.;Zhijie Wu.;Cengceng Zhang.;Yiying Zhang.;Xiaoyan Dong.;Hui Xiong.;Xiaobing Wu.;Zhichun Feng.
来源: N Engl J Med. 2025年392卷24期2438-2446页

Four patients with infantile-onset Pompe's disease received a single intravenous injection of an adeno-associated virus serotype 9 vector carrying codon-optimized complementary DNA encoding human acid α-glucosidase (GAA) (dose, 1.2 × 1014 vector genomes per kilogram of body weight). One patient was withdrawn from the study and subsequently died. The other patients had improvement in cardiac outcomes and motor function over a 52-week observation period. Anti-GAA antibodies were not detected in any of the patients during the observation period. Respiratory tract infections were the most common adverse events. (Funded by the National Natural Science Foundation of China and National High Level Hospital Clinical Research Funding; Chinese Clinical Trial Registry number, ChiCTR2200063229.).

1133. The Role of Public Health Agencies in Creating Vaccine Policy.

作者: Peter Marks.
来源: N Engl J Med. 2025年393卷3期209-211页

1134. Transforming Health Care - Shared Commitments for a Learning Health System.

作者: James L Madara.;Suzanne Miyamoto.;Sean C Dowdy.;Sarah M Greene.;Julie Tarrant.;Peter A Margolis.
来源: N Engl J Med. 2025年393卷2期192-197页

1135. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.

作者: Ania M Jastreboff.;Donna H Ryan.;Harold E Bays.;Peter R Ebeling.;Mia G Mackowski.;Nisha Philipose.;Leorah Ross.;Yimeng Liu.;Cassandra E Burns.;Siddique A Abbasi.;Nicola Pannacciulli.; .
来源: N Engl J Med. 2025年393卷9期843-857页

Maridebart cafraglutide (known as MariTide) is a long-acting peptide-antibody conjugate that combines glucagon-like peptide-1 receptor agonism and glucose-dependent insulinotropic polypeptide receptor antagonism and that is intended for the treatment of obesity.

1136. Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy.

作者: Julio Rosenstock.;Timothy Bailey.;Lisa Connery.;Eden Miller.;Cyrus Desouza.;Qianqian Wang.;Jennifer Leohr.;Alastair Knights.;Molly C Carr.;Christopher J Child.; .
来源: N Engl J Med. 2025年393卷4期325-335页

In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to fasting blood glucose levels. A fixed-dose regimen of insulin efsitora alfa (efsitora), a once-weekly basal insulin, may provide a benefit in adults with type 2 diabetes who have not received previous insulin therapy.

1137. Weekly Insulins and Therapeutic Burden in Type 2 Diabetes.

作者: Julie R Ingelfinger.;Clifford J Rosen.
来源: N Engl J Med. 2025年393卷4期401-402页

1138. The Health Equity, Medical, and Scientific Costs of Dismantling DEI.

作者: Crystal W Cené.
来源: N Engl J Med. 2025年392卷24期2396-2399页

1139. Cutaneous Extramedullary Plasmacytoma after Bone Fracture.

作者: Madeline Conlon.;Katie McBee.
来源: N Engl J Med. 2025年392卷24期e56页

1140. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.

作者: Julio Rosenstock.;Stanley Hsia.;Luis Nevarez Ruiz.;Sarah Eyde.;David Cox.;Wen-Shuo Wu.;Rong Liu.;Jianghao Li.;Laura Fernández Landó.;Max Denning.;Lisa Ludwig.;Yanyun Chen.; .
来源: N Engl J Med. 2025年393卷11期1065-1076页

Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy and safety of orforglipron are needed.

结果排序

文献格式

出版时间

出版类型

出版语言